Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

201192 citationsReviewgold Open Access

Authors

André Bacellar Costa Lima · Universidade Estadual de Campinas (UNICAMP)

Lígia Traldi Macedo · Universidade Estadual de Campinas (UNICAMP)

André Deeke Sasse · Centro de Pesquisas Oncológicas

Abstract

The addition of bevacizumab to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and RR. Considering the toxicities added, and the small absolute benefits found, bevacizumab plus platinum-based chemotherapy can be considered an option in selected patients with advanced NSCLC. However, risks and benefits should be discussed with patients before decision making.

Topics & Keywords

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 6, Issue 8, pp. e22681-e22681

DOI: 10.1371/journal.pone.0022681

Field-Weighted Citation Impact: 7.71